It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BEAM’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BEAM’s TA Score shows that 6 TA indicator(s) are bullish while DNA’s TA Score has 5 bullish TA indicator(s).
BEAM (@Biotechnology) experienced а +6.51% price change this week, while DNA (@Biotechnology) price change was +0.70% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.68%. For the same industry, the average monthly price growth was +33.10%, and the average quarterly price growth was +8.38%.
BEAM is expected to report earnings on Feb 27, 2024.
DNA is expected to report earnings on Mar 25, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
|BEAM||DNA||BEAM / DNA|
1 day ago76%
1 day ago83%
1 day ago84%
1 day ago78%
1 day ago87%
1 day ago72%
1 day ago88%
1 day ago82%
1 day ago86%
1 day ago83%
1 day ago84%
1 day ago85%
6 days ago82%
10 days ago76%
17 days ago88%
8 days ago84%
1 day ago79%
1 day ago81%
1 day ago89%
|ETFs / NAME||Price $||Chg $||Chg %|
|First Trust NASDAQ® Cln Edge® GrnEngyETF|
|ProShares UltraShort Russell2000|
|Goldman Sachs Community Municipal Bd ETF|
|Entergy Mississippi LLC|
|First Trust Mid Cap Growth AlphaDEX® ETF|
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.